ThromboGenics announced that it has resubmitted a Biologics License Application (BLA) with the FDA for ocriplasmin intravitreal injection 2.5mg/mL for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.